Россииское кардиологическое общество Российское научное медицинское общество терапевтов Антигипертензивная лига
 Скачать 3.62 Mb.
|
|
2117–2128. 150. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment // Trends in Endocrinology & Metabolism. 2012. Vol. 23. № 5. P. 205–215. 151. Wright A. et al. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy // Ann Intern Med. 1998. Vol. 128. № 3. P. 165–175. 152. Proks P et al. Sulfonylurea stimulation of insulin secretion //Diabetes. 2002. № 51 (suppl 3). P. S368–S376. 153. Rao AD et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? 142 A meta-analysis of observational studies //Diabetes care. 2008. Vol. 31. № 8. P. 1672–1678. 154. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta ‐analysis of randomized clinical trials // Diabetes, Obesity and Metabolism. 2013. Vol. 15. № 10. P. 938–953. 155. Sherifali D et al. The Effect of Oral Antidiabetic Agents on A1C Levels A systematic review and meta-analysis // Diabetes care. 2010. Vol. 33. № 8. P. 1859–1864. 156. Nishimura R. [The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)] // Nihon rinsho. Japanese journal of clinical medicine. 2005. Vol. 63. P. 478–482. 157. Чазова И. Ε., Мычка В. Б., Беленков Ю. Н. Основные результаты программы АПРЕЛЬ // Cons med. 2005. С. 18–22. 158. Hubert HB et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study // Circulation. 1983. Vol. 67. № 5. P. 968–977. 159. Mancia G et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) //Blood pressure. 2013. Vol. 22. № 4. P. 193–278. 160. Fitchett D. Clinical trial update: focus on the ONTARGET study //Vascular health and risk management. 2007. Vol. 3. № 6. P. 901. 161. Sleight P et al. Blood-pressure reduction and cardiovascular risk in HOPE study //The Lancet. 2001. Vol. 358. № 9299. P. 2130–2131. 162. Hanley AJ et al. Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose The DREAM trial // Diabetes Care. 2010. Vol. 33. № 3. P. 608–613. 163. Konstam MA et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators //Circulation. 1992. Vol. 86. № 2. P. 431–438. 164. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy // The Lancet. 2000. Vol. 355. № 9200. P. 253–259. 165. Penno G et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM // Diabetes. 1998. Vol. 47. № 9. P. 1507–1511. 166. Abbott KC, Bakris GL. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction // Progress in brain research. 2002. Vol. 139. P. 289–298. 167. REID JL. Plaque hypertension lipid-lowering Italian study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects // Journal of hypertension. Supplement. 1993. Vol. 11. № 5. P. S314–S315. 168. Lonn EM. et al. Effects of ramipril and vitamin E on atherosclerosis the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) // Circulation. 2001. Vol. 103. № 7. P. 919–925. 143 169. ARB Trialists Collaboration et al. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals //Journal of hypertension. 2011. Vol. 29. № 4. P. 623–635. 170. Weber MA. Angiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes? //European Heart Journal Supplements. 2003. Vol. 5. № suppl C. P. C1–C4. 171. Verdecchia P. et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention //Hypertension. 2005. Vol. 46. № 2. P. 386–392. 172. Costanzo P et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients // Journal of hypertension. 2009. Vol. 27. № 6. P. 1136–1151. 173. Reisin E, Weir M et. al. Lisinopril Versus Hydrochlorothiazide in Obese Hypertensive Patients. Hypertension. 1997; 30:140-145 174. Grassi G, Seravalle G, Dell’Oro R et al. Comparative effects of candesartan and hydrocholorothiazide on blood pressare, insulin sensitivity and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003;21:1761-17. 175. Engberink RHGO. et al. Effects of Thiazide-Type and Thiazide-Like Diuretics on Cardiovascular Events and Mortality Systematic Review and Meta- Analysis // Hypertension. 2015. Vol. 65. № 5. P. 1033–1040. 176. Мычка В. Б., Чазова И. Е. Российская доказательная медицина– программа МИНОТАВР: преимущества ретардной формы индапамида при лечении метаболического синдрома // Consilium medicum. 2006. Vol. 8. № 5. С. 46–49. 177. Срожидинова Н. З., Тухтаев А. А. Эффективность моксонидина в лечении артериальной гипертензии у больных с метаболическим синдромом / /Артериальная гипертензия. 2013. № 3 (29). 178. Чазова И. Е., Мычка В. Б. Новые возможности в лечении больных с метаболическим синдромом (результаты исследования ALMAZ) //Системные гипертензии. 2006. № 2. С. 55–60. 179. Dalhof B, Sever PS, Poulter NR, Wedel H, Beevers DG et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindoprilas required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) a multicentre randomised controlled trial. Lancet 2005;366:895– 906. 180. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–1003 181. Mancia G, Grassi G, Zanchetti A. New onset diabetes and antihypertensive drugs. J Hypertens 2006; 24:3–10. 182. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.AADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Lancet. 2007 Sep 8;370(9590):829-40. 144 183. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417–2428 184. Katayama S et al. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study // Hypertension Research. 2007. Vol. 30. № 6. P. 529–533. 185. Waters J et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension-results of the TOPIC (Trial Of Physiotens In Combination) Study //Journal of Clinical and Basic Cardiology. 1999. Vol. 2. № 2. P. 219–224. 186. Hubacek JA et al. FTO variant, energy intake, physical activity and basal metabolic rate in Caucasians. The HAPIEE study // Physiological research: Academia Scientiarum Bohemoslovaca. 2011. Vol. 60. № 1. P. 175. 187. Kuulasmaa K et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations // The Lancet. 2000. Vol. 355. № 9205. P. 675–687. 188. Mihaylova B et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials // The Lancet. 2012. Vol. 380. № 9841. P. 581–590. 189. Sarwar N et al. Triglycerides and the risk of coronary heart disease 10 158 incident cases among 262 525 participants in 29 western prospective studies //Circulation. 2007. Vol. 115. № 4. P. 450–458. 190. Chapman MJ et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management // European heart journal. 2011. P. ehr112. 191. Fruchart JC et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients // Diabetes and Vascular Disease Research. 2008. Vol. 5. № 4. P. 319–335. 192. Voight BF et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study // The Lancet. 2012. Vol. 380. № 9841. P. 572–580. 193. Lemos J, de et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta- ‐analysis of data from 170,000 participants in 26 randomised trials //Lancet. 2010. Vol. 376. № 9753. P. 1670-81. 194. Colhoun HM et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial //The Lancet. 2004. Vol. 364. № 9435. P. 685–696. 195. Heart Protection Study Collaborative Group et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial //The Lancet. 2002. Vol. 360. № 9326. P. 7–22. 196. Nissen SE et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial // Jama. 2006. Vol. 295. № 13. P. 1556–1565. 197. Preiss D et al. Lipid-modifying therapies and risk of pancreatitis: a meta- analysis //JAMA. 2012. Vol. 308. № 8. P. 804–811. 198. Taylor F et al. Statins for the primary prevention of cardiovascular disease //Cochrane Database Syst Rev. 2013. Vol. 1. № 1. 145 199. Mortensen MB et al. Primary prevention with statins: ACC/AHA risk- based approach versus trial-based approaches to guide statin therapy //Journal of the American College of Cardiology. 2015. Vol. 66. № 24. P. 2699–2709. 200. LaRosa J, Reiffel J, Gotto Jr A. Statins: Do They Have Beneficial Effects Over and Above Their Actions on Lipids? // The Medical Roundtable Cardiovascular Edition. 2015. 201. Bosch J, Forns X. Therapy: Statins and liver disease: from concern to'wonder'drugs? //Nature Reviews Gastroenterology & Hepatology. 2015. 202. Finegold JA et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice // European journal of preventive cardiology. 2014. Vol. 21. № 4. P. 464–474. 203. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti- dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction // Cardiovasc Diabetol. 2012. Vol. 11. № 125. P. 1475–2840. 204. Keene D et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients //Bmj. 2014. Vol. 349. P. g4379. 205. Nordmann AJ et al. Fibrates for primary prevention of cardiovascular disease events //The Cochrane Library. 2012. 206. Jun M et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis //Journal of the American College of Cardiology. 2012. Vol. 60. № 20. P. 2061–2071. 207. Sudhop T, von Bergmann K. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins] //MMW Fortschritte der Medizin. 2003. Vol. 145. № 16. P. 48–50. 208. Seishima M [Treatment for dyslipidemia — a strategy for the prevention of atherosclerosis] // Rinsho byori. The Japanese journal of clinical pathology. 2013. Vol. 61. № 4. P. 334–341. 209. Plourde B, Sarrazin JF, Nault I, Poirier P. Sudden cardiac death and obesity. Expert Rev Cardiovasc Ther 2014; 12:1099-110. 210. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-77. 211. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol 1977; 39: 452-8. 212. McGill HC Jr, McMahan CA, Herderick EE et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002;105:2712-8. 213. See R, Abdullah SM, McGuire DK, et al. The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. J Am Coll Cardiol 2007;50:752-9. 214. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52. 215. Kragelund C, Hassager C, Hildebrandt P, Torp-Pedersen C, Kober L. Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol 2005;98:123-31. 146 216. Lee HW, Hong TJ, Hong JY, Choi JH, Kim BW, Ahn J, Park JS, Oh JH, Choi JH, Lee HC, Cha KS. Korea Working Group on Myocardial Infarction Investigators. Waist-hip ratio and 1-year clinical outcome in patients with non- ST-elevation myocardial infarctions. Coron Artery Dis. 2016;27: 357-64. 217. Benderly M, Boyko V, Goldbourt U. Relation of body mass index to mortality among men with coronary heart disease. Am J Cardiol 2010;106: 297- 304 218. Starr JW, Wagner GS, Behar VS, Walston A, Greenfield JC. Vectorcardiographic criteria for the diagnosis of inferior myocardial infarction. Circulation 1974; 49: 829-36.. 219. Alpert MA, Terry BE, Cohen MV et al. The electrocardiogram in morbid obesity. AmJCardiol 2000; 85: 908-10. 220. Abergel E, Tase M, Menard J, Chatellier G. Influence of obesity on the diagnostic value of electrocardiographic criteria for detecting left ventricular hypertrophy. Am J Cardiol 1996;77:739-44. 221. Casale PN, Devereux RB, Kligfield P et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. JAmCollCardiol 1985;6:572-80. 222. Cuspidi C, Rescaldani M, Sala C, Grassi G. Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies. JHypertens 2014; 32:16-25. 223. Wong CY, O’Moore-Sullivan T, Leano R et al. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004;110:3081-7. 224. Ansari A, Rholl AO. Pseudopericardialeffusion: echocardiographic and computed to mographicc or relations. ClinCardiol 1986;9:551-5. 225. Bires AM, Lawson D, Wasser TE, Raber-Baer D. Comparison of Bruce treadmill exercise test protocols: is ramped Bruce equal or superior to standard bruce in producing clinically valid studies for patients presenting for evaluation of cardiac ischemia or arrhythmia with body mass index equal to or greater than 30? JNuclMedTechnol 2013;41:274-8. 226. Legault S, Senechal M, Bergeron S et al. Usefulness of an accelerated transoesophageal stress echocardiography in the preoperative evaluation of high risk severely obese subjects awaiting bariatric surgery. CardiovascUltrasound 2010;8:30. 227. Chow BJ, Dorbala S, DiCarli MF et al. Prognostic value of PET myocardial perfusion imaging in obese patients. JACCCardiovascImaging 2014;7:278-87. 228. Zaremski L, Quesada R, Kovacs M, Schernthaner M, UthoffH. Prospective comparison of palpation versus ultrasound — guide dradial access for cardiac catheterization. JInvasiveCardiol 2013;25:538-42. 229. Wong P, Harding S, Walters D, Hull ML, Jang IK. Vascular complications after hemostatic puncture closure device (Angio-Seal) are not higher in overweight patients. JInvasiveCardiol 2001;13:623-5. 230. Payvar S, Kim S, Rao SV et al. In-hospital outcomes of percutaneous coronary interventions in extremely obese and normal-weight patients: findings from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 2013;62:692-6. 231. Buschur ME, Smith D, Share D et al. The burgeoning epidemic of morbid obesity in patients undergoing percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J Am Coll Cardiol 2013;62:685-91. 147 232. Oreopoulos A, Padwal R, Norris CM et al. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity (Silver Spring) 2008;16:442-50. 233. Li YH, Lin GM, Lin CL, Wang JH, Han CL. Relation of body mass index to mortality among patients with percutaneous coronary intervention longer than 5 years follow-up: a meta-analysis. Int J Cardiol 2013;168:4315-8. |